Hyperhomocysteinemia is an independent risk factor for cardiovascular disease.
Radix Astragali is the dried root of Astragalus membranaceus (FISCH.) BGE. var. mongholicus (BGE.) HSIAO or Astragalus membranaceus (FISCH.) BGE. It has been widely used in Chinese medicine since ancient times for the improvement of immune disorders and management of cardiovascular diseases with an excellent safety. 12) Research suggests that this herb was able to inhibit free radicals, decreases lipid peroxidation, and increases antioxidant enzymes. 13) Many medicinally active compounds have been isolated from this plant, including polysaccharides, flavones and astragalosides. Astragalosides is the major active component extracted from the root of Astragalus membranaceus. 12) Previous studies from our laboratory demonstrated that crude astragalosides fraction can potently protect endothelium-dependent relaxation against the acute injury from HCY through nitric oxide regulatory pathways, in which antioxidation played a key role. 14) Astragaloside IV (AST-IV), 3-o-beta-D-xylopyranosyl-6-obeta-D-glucopyranosyl-cycloastragenol ( Fig. 1) , was a small molecular saponin. AST-IV can exert multipotent activities under pathophysiological conditions, such as anti-hypertension, 15) positive inotropic action, 16) anti-inflammation, 17) and anti-infarction. 18) Up to now, however, whether AST-IV has an exact protective effect on vessels in hyperhomocysteinemia and the mechanism are not known. The aim of the present study is to examine the effect of AST-IV on vasomotor dysfunction induced by HCY in rat aorta and explore the underlying mechanism.
MATERIALS AND METHODS

Materials
The AST-IV used in this study was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China), with a high purity 99% by HPLC analysis. Phenylephrine (PE), acetylcholine (ACH), HCY, sodium nitroprusside (SNP), N w -nitro-L-arginine methyl ester hydrochloride (L-NAME) and superoxide dismutase (SOD)-polyethylene were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 5-(6)-Chloromethyl-2Ј,7Ј-dichloro-dihydrofluorescein diacetate (CM-H 2 DCF-DA) was from Molecular Probes Inc. (Eugene, U.S.A.). All chemicals were of the highest purity available.
Organ Chamber Experiment Animals used in this study were experimentally naive male Sprague-Dawley (SD) rats obtained from Experiment Animal Center of Zhejiang Academy of Medical Sciences, China. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Rats were killed by cervical dislocation. Thoracic arterial rings were prepared according to the method described previously by Zhang et al. 19) For isometric force recording, aortic rings were mounted between two stainless steel hooks and suspended in the organ bath containing Krebs' buffer, composed of (mM): NaCl, 118; KCl, 4.7; MgSO 4 · 7H 2 O, 1.2; KH 2 PO 4 , 1.2; CaCl 2 , 2.5; NaHCO 3 , 25; and glucose, 11; at 37°C bubbled with 95% O 2 ϩ5% CO 2 (pH 7.4). The tension of the aortic ring was monitored by a force transducer (Nanjing Medease Science and Technology Co., Ltd., China), connected to MedLab 5.0v, a computer-based data acquisition system (Nanjing Medease Science and Technology Co., Ltd., China). After equilibrium for 60 min at 2.0 g resting tension, then rings were challenged with KCl (6.0ϫ10 Ϫ2 mol/l) repeatedly until a reproducible maximal contractile response was obtained. The integrity of the endothelium was assessed in all preparations by determining the ability of ACH (10 mmol/l) to induce more than 80% relaxation of rings pre-treated with PE (1 mmol/l). Then rings was serially washed and used for the following experiment.
Bioassay of Vasoreactivity To assess the effect of HCY on vasorelaxation, rings were incubated with Krebs buffer for 30 min and then exposed to HCY (0.1-3 mmol/l) for 60 min. After the incubation, the endothelium-dependent or independent response curve was evoked by ACH (0.01-10 mmol/l) or SNP (0.01-10 mmol/l) to PE (1 mmol/l)-induced contraction.
In the subsequent experiments, the effect of AST-IV on vasomotor dysfunction induced by HCY in rat aorta and the underlying mechanism were determined. Some rings were pretreated with different concentrations of AST-IV (5, 10, 50, and 100 mg/ml) for 30 min; some rings were preincubated with SOD (0.6, 1.2, and 1.8 KU/l) alone or coincubated with SOD (1.2 KU/l) and AST-IV (100 mg/ml) for 30 min; and the other rings were exposed to L-NAME (100 mmol/l) with or without AST-IV (100 mg/ml) for 30 min. Continuously, HCY (1 mmol/l) were administrated to co-incubate the rings in each group for another 60 min. Then, the rings were recontracted with 1.0 mmol/l PE, and endothelium-dependent responses to ACH were repeated.
Cellular Experiments Human umbilical vein endothelial cells (HUVECs) were isolated and cultured as previously described. 20) HUVECs from passages 3-4 were used in this study. For cell culture experiment, HUVECs were incubated with medium, AST-IV (5, 10, 50, and 100 mg/ml), SOD (1.2, and 1.8 KU/l) alone, and AST-IV (100 mg/ml) plus SOD (1.2 KU/l) for 30 min before treatment with HCY (0.1 or 1 mmol/l) for 60 min. After above treatment, the supernatant and cultured cells were collected respectively. Cells were counted with microscopy and cellular protein concentrations were determined using a protein assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Assay of NO Level The amount of NO released by cells was determined using a NO assay kit according to the manufacturer's protocol (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The amount of NO metabolites (nitrate and nitrite), which were more stable than NO, was measured by nitric acid reductase method.
21)
Assay of NO Synthase (NOS) Activity The collected cells were disrupted with ultrasonic wave. NOS enzymatic activity in the cultured cells was determined from the rate of conversion of L-arginine to L-citrulline using a NOS assay kit according to the manufacturer's protocol (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
22)
Measurement of Intracellular ROS Levels For intracellular fluorescence measurement of ROS, some HUVECs were loaded with the probe CM-H 2 DCF-DA for 30 min at 37°C. CM-H 2 DCF-DA fluorescence was monitored using a fluorescence microscope (Nikon TE2000, Japan) (excitation 495 nm, emission 520 nm). The fluorescent intensities were recorded and analyzed by a charge-coupled device Camera (CoolSNAP HQ; Nippon Roper, Chiba, Japan) with an image analysis system (MetaMorph; Nippon Roper).
Assay of SOD Activity SOD activity in the cultured cells was determined by inhibition of nitroblue tetrazolium reduction due to superoxide anion generation by xanthinexanthine oxidase system using a SOD activity assay kit according to the manufacturer's protocol (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
23)
Statistical Analysis The ACH-induced maximal relaxation (E max ) in aortic rings was calculated as a percentage of the contraction in response to PE (1 mmol/l). The half maximum effective concentration (EC 50 ) was designated as the concentration of ACH that induced 50% of maximum relaxation from the contraction elicited by PE (1 mmol/l). These values were determined by nonlinear regression of the log concentration-response curves. Sensitivity was expressed as pD 2 (Ϫlog EC 50 ). All values are expressed as meanϮS.E.M. Statistical analysis was performed with one-way ANOVA followed by Newman-Keuls test. Differences were accepted as statistically significant at p values Ͻ0.05 (Graph Pad Prism).
RESULTS
Organ Chamber Experiment
In each group, a sustained vascular contraction with a peak tension of about 2.65Ϯ0.31 g was induced by PE (1 mmol/l). In any group, no difference in relaxation responses to ACH (10 mmol/l) in aortic rings was observed at the initial experiment.
Compared with the control group (E max : 98.37Ϯ0.65%, pD 2 : 6.88Ϯ0.05), HCY (0.1-3 mmol/l) treatment inhibited endothelium-dependent relaxation evoked by ACH, and the E max fell to 84.90Ϯ1.01%, 76.99Ϯ1.56%, 65.20Ϯ1.50%, and 51.18Ϯ1.89%, with a reduction of pD 2 (6.74Ϯ0.06, 6.62Ϯ 0.05, 6.53Ϯ0.05, and 6.50Ϯ0.05). There was no significant difference of pD 2 was found between 1 mmol/l and 3 mmol/l HCY group, although E max exerted a further reduction (Fig.  2) . Moreover, HCY (0.1-3 mmol/l) failed to deteriorate the endothelium-independent relaxation to SNP (data not shown). Therefore, 1 mmol/l HCY treatment-induced inhibition of endothelium-dependent relaxation to ACH was used in the subsequent experiment as a control.
Treatment with AST-IV (50 or 100 mg/ml) was able to improve the inhibition of endothelium-dependent relaxation induced by HCY (1 mmol/l). E max and pD 2 were shown as (74.67Ϯ2.10% or 81.73Ϯ1.87% versus 65.20Ϯ1.50%, pϽ0.05) and (6.78Ϯ0.06 or 6.87Ϯ0.06 versus 6.53Ϯ0.05, pϽ0.05), respectively. Additionally, due to the presence of L-NAME (100 mmol/l), the inhibitor of nitric oxide synthase (NOS), AST-IV (100 mg/ml) failed to show any ameliorating effect on endothelium-dependent vasomotor response caused by HCY (1 mmol/l) (Fig. 3) .
To confirm the oxidative effect of HCY on endotheliumdependent relaxation, SOD was used. With the increase of the concentration of SOD in organ bath (0.6, 1.2, and 1.8 KU/l), a more significant effect was observed (E max : 70.59Ϯ1.72%, 82.18Ϯ1.26%, and 93.51Ϯ1.30% versus 65.20Ϯ1.50%; pD 2 : 6.68Ϯ0.06, 6.91Ϯ0.06, and 9.94Ϯ0.06 versus 6.53Ϯ0.05) and the inhibitory effect of HCY was almost completely abolished. In an analogous manner, combined treatment of the rings with AST-IV (100 mg/ml) and SOD (1.2 KU/l) totally reversed the HCY-induced impairment of endothelium-dependent relaxation (E max : 95.10Ϯ 2.04%; pD 2 : 6.91Ϯ0.06), which was very similar to the effect of 1.8 KU/l SOD group (Fig. 4) .
Cellular Experiments Incubation of HUVECs with HCY (0.1 or 1 mmol/l) for 60 min resulted in the reduction both of NO content and NOS activity. Treatment with AST-IV (50 and 100 mg/ml) was able to attenuate the inhibition both of NO content and NOS activity. Furthermore, SOD (1.8 KU/l) exerted more significant ameliorating effects on these parameters than AST-IV (100 mg/ml). Meanwhile, combined treatment with SOD (1.2 KU/l) and AST-IV (100 mg/ml) induced a similar effect with SOD (1.8 KU/l) (Figs. 5, 6 ).
Compared to the control group, treatment with HCY (1 mmol/l) for 60 min significantly increased the ROS level and decreased the SOD activity in HUVECs. AST-IV (10, 50, and 100 mg/ml) markedly prevented this accumulation of ROS and reduction of SOD activity. However, AST-IV showed a lower potency than SOD (Figs. 7, 8) . 
DISCUSSION
The present study indicated that AST-IV improved the endothelium dysfunction induced by HCY. Furthermore, a favorable mechanism on activation of NO pathway through the antioxidant defense has been postulated.
Hyperhomocysteinemia is considered an established risk factor for atherosclerosis. Increased HCY levels are found in 40% of patients with coronary, cerebral or peripheral artery diseases, and only in 15% of healthy individuals. 24) Accumulating evidence suggests a significant role of altered cellular redox reactions in the vascular phenotype of hyperhomocysteinemia. 25) Redox effects are particularly important in mediating the adverse effects of hyperhomocysteinemia on the endothelium, leading to loss of endothelium-derived nitric oxide and vasomotor dysfunction.
Consistent with the previous report, the endothelial specificity of HCY was clearly demonstrated in that a significant effect on endothelium-dependent relaxation to ACH was seen both in our present and previous studies. 14, 26) The result of this study that HCY did not alter the relaxation responses to SNP and the other observation that SNP-induced relaxation in endothelium-denuded tissues was also unaffected by HCY 27) would tend to support the hypothesis that the HCYinduced vasomotor dysfunction occurs within endothelial rather than vascular smooth muscle cells.
A reduction in both bioavailability and production of endothelium-derived NO is the hallmark of endothelial dysfunction. NO produced through the calcium-dependent activation of endothelial nitric oxide synthase in endothelial cells diffuses into the adjacent vascular muscle layer, and causes its relaxation by activity of cGMP pathway. 28) In agreement with previous reports, 21, 29) our data suggested that both NOS activity and NO formation were inhibited by HCY in HUVECs. Thus, we have shown HCY impaired endothelial dysfunction mediated by NOS-NO pathway.
Redox reactions resulting in increased vascular levels of ROS may play an important role in mediating endothelial dysfunction, particularly the loss of endothelium-derived NO, during hyperhomocysteinemia. The present study indicated that HCY significantly increased intracellular ROS lev- els and decreased the SOD activity in HUVECs, which was consistent with the reported by Lin et al. 30) Treatment with SOD, an antioxidant enzyme, reversed the HCY-impaired endothelium-dependent vasomotor responses. Other researchers have suggested that SOD showed similar protective effects on injury aorta, pulmonary artery, or skeletal muscle arterioles. 27) During these years, natural products with antioxidant activity have drawn the most attention. Astragalus membranaceus is widely used for prevention of ROS-mediated injury in pathological situation through its antioxidant properties. 13, [31] [32] [33] In an in vitro study, it was demonstrated by electron paramagnetic resonance imaging technique that Astragalus membranaceus can potently inhibit ROS produced by the dimethyl sulphoxide system and scavenge over 90% of ROS. 34) Recently, the emerging experiments reported that a herbal formulation, comprising Astragalus membranaceus, improved the pancreatic beta cell function via the antioxidative effect. 35, 36) Furthermore, total saponins extracted from Astragalus membranaceus had the effects on enhancing free radical removal and decreasing lipid peroxidation, thus preventing the calcium overload in isoproterenol-treated cardiomyocytes. 37) According to our previous study, it has been shown that total saponins isolated from Astragalus membranaceus ameliorated endothelium-dependent relaxation injured by HCY via scavenging free radical species.
14)
Astragalus membranaceus contains a series of cycloartane triterpene glycosides denoted astragalosides I-VII (saponins), which are based on the aglycone cycloastragenol and contain from one to three sugars attached at the 3-, 6-, and 25-positions.
12) AST-IV is regarded as the main criterion of for quality control of Astragalus membranaceus in the Pharmacopoeia of the People's Republic of China. 38) There is emerging evidence that AST-IV has the biological property of eliminating ROS, due to which it protects cardiomyocytes from oxidative stress-mediated injury under hypoxic conditions, delays the aging effect in rats treated by hydrocortisone, and protects coxsackievirus B3-induced murine myocarditis. 33, 39, 40) In the present study, we have shown that AST-IV is effective in protecting endothelium-dependent vasomotor function from injury by HCY, and this ameliorating effect of AST-IV was attenuated by L-NAME, a NOS inhibitor. In order to clarify whether this effect of AST-IV was exerted through NO pathway, we tested the influence of AST-IV on NO pathway in endothelial cells. The result showed that AST-IV was able to improve content of NO and activity of NOS. However, whether the beneficial effects of AST-IV on vascular endothelial dysfunction injured by HCY are related with scavenging ROS remain largely unknown. It is worth noting that AST-IV not only scavenged OH Ϫ generated from the Fenton reaction in an in vitro reaction system, 41) but also entered cells and upregulation of SOD content and activity. 40) This study provided detailed information that AST-IV inhibited the production of ROS and improved the SOD activity in endothelial cells incubated by HCY. Moreover, SOD, a scavenger of superoxide anions showed a similar but higher maximum effect than AST-IV.
In summary, it was demonstrated for the first time that AST-IV has the ability to regulate NO pathway impaired by HCY through antioxidant defense. In light of these findings, it could lead to the development of a new therapy for the vascular lesion in the pathological condition characterized by elevation of HCY in blood plasma.
